JP2018522013A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018522013A5 JP2018522013A5 JP2018502404A JP2018502404A JP2018522013A5 JP 2018522013 A5 JP2018522013 A5 JP 2018522013A5 JP 2018502404 A JP2018502404 A JP 2018502404A JP 2018502404 A JP2018502404 A JP 2018502404A JP 2018522013 A5 JP2018522013 A5 JP 2018522013A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- nucleic acid
- composition according
- acid polymer
- truncated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 31
- 150000007523 nucleic acids Chemical class 0.000 claims 21
- 108020004707 nucleic acids Proteins 0.000 claims 20
- 102000039446 nucleic acids Human genes 0.000 claims 20
- 229920000642 polymer Polymers 0.000 claims 17
- 101150117329 NTRK3 gene Proteins 0.000 claims 11
- 101150056950 Ntrk2 gene Proteins 0.000 claims 10
- 239000013598 vector Substances 0.000 claims 9
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 229920001983 poloxamer Polymers 0.000 claims 4
- 229960000502 poloxamer Drugs 0.000 claims 4
- 208000032625 disorder of ear Diseases 0.000 claims 3
- 239000002679 microRNA Substances 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 206010011878 Deafness Diseases 0.000 claims 2
- -1 Ethylene nucleic acid Chemical class 0.000 claims 2
- 208000027530 Meniere disease Diseases 0.000 claims 2
- 108010025020 Nerve Growth Factor Proteins 0.000 claims 2
- 102000007072 Nerve Growth Factors Human genes 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 108091093037 Peptide nucleic acid Proteins 0.000 claims 2
- 108091027967 Small hairpin RNA Proteins 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 230000003197 catalytic effect Effects 0.000 claims 2
- 231100000888 hearing loss Toxicity 0.000 claims 2
- 230000010370 hearing loss Effects 0.000 claims 2
- 208000016354 hearing loss disease Diseases 0.000 claims 2
- 108091070501 miRNA Proteins 0.000 claims 2
- 125000003835 nucleoside group Chemical group 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims 2
- 239000004055 small Interfering RNA Substances 0.000 claims 2
- 239000013603 viral vector Substances 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 1
- 108020005345 3' Untranslated Regions Proteins 0.000 claims 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 claims 1
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-dimethylaminopyridine Substances CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims 1
- 241000710929 Alphavirus Species 0.000 claims 1
- 206010011891 Deafness neurosensory Diseases 0.000 claims 1
- 206010011903 Deafness traumatic Diseases 0.000 claims 1
- 239000005977 Ethylene Substances 0.000 claims 1
- 206010063491 Herpes zoster oticus Diseases 0.000 claims 1
- 108700011259 MicroRNAs Proteins 0.000 claims 1
- 206010029240 Neuritis Diseases 0.000 claims 1
- 208000002946 Noise-Induced Hearing Loss Diseases 0.000 claims 1
- IKRKJHFXRDRMDN-UHFFFAOYSA-N OP(OCN1CCOCC1)=O Chemical class OP(OCN1CCOCC1)=O IKRKJHFXRDRMDN-UHFFFAOYSA-N 0.000 claims 1
- 206010033109 Ototoxicity Diseases 0.000 claims 1
- 206010036626 Presbyacusis Diseases 0.000 claims 1
- 208000009966 Sensorineural Hearing Loss Diseases 0.000 claims 1
- 241000700584 Simplexvirus Species 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 208000009205 Tinnitus Diseases 0.000 claims 1
- 241000700618 Vaccinia virus Species 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 230000006835 compression Effects 0.000 claims 1
- 238000007906 compression Methods 0.000 claims 1
- 208000005457 endolymphatic hydrops Diseases 0.000 claims 1
- 230000003492 excitotoxic effect Effects 0.000 claims 1
- 231100000063 excitotoxicity Toxicity 0.000 claims 1
- 201000011349 geniculate herpes zoster Diseases 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 231100000262 ototoxicity Toxicity 0.000 claims 1
- 150000008300 phosphoramidites Chemical class 0.000 claims 1
- 229920001992 poloxamer 407 Polymers 0.000 claims 1
- 229940044476 poloxamer 407 Drugs 0.000 claims 1
- 230000001177 retroviral effect Effects 0.000 claims 1
- 231100000879 sensorineural hearing loss Toxicity 0.000 claims 1
- 208000023573 sensorineural hearing loss disease Diseases 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 231100000886 tinnitus Toxicity 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562198062P | 2015-07-28 | 2015-07-28 | |
| US62/198,062 | 2015-07-28 | ||
| PCT/US2016/044570 WO2017019905A1 (en) | 2015-07-28 | 2016-07-28 | Treatment using truncated trk b and trk c antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018522013A JP2018522013A (ja) | 2018-08-09 |
| JP2018522013A5 true JP2018522013A5 (enExample) | 2019-09-05 |
| JP6923509B2 JP6923509B2 (ja) | 2021-08-18 |
Family
ID=57884960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018502404A Active JP6923509B2 (ja) | 2015-07-28 | 2016-07-28 | 切断型のｔｒｋｂおよびｔｒｋｃのアンタゴニストを使用する処置 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US10066229B2 (enExample) |
| EP (1) | EP3328440A4 (enExample) |
| JP (1) | JP6923509B2 (enExample) |
| WO (1) | WO2017019905A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10066229B2 (en) | 2015-07-28 | 2018-09-04 | Otonomy, Inc. | Treatment using truncated Trk B and Trk C antagonists |
| EP3406259A1 (en) * | 2017-05-24 | 2018-11-28 | Dompé farmaceutici S.p.A. | Neurotrophins for use in the treatment of hearing loss |
| EP3820483A4 (en) * | 2018-07-13 | 2023-03-01 | Yale University | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ENDOMETRIOSIS |
| US11911416B2 (en) | 2018-08-01 | 2024-02-27 | University Of Iowa Research Foundation | Compositions and methods to restore hearing loss and balance through embryonic ear transplant |
| JP2022511026A (ja) * | 2018-12-04 | 2022-01-28 | シリオン・バイオテック・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | ポロキサミンを使用するウイルスの形質導入 |
| US10561736B1 (en) | 2019-01-09 | 2020-02-18 | Spiral Therapeutics, Inc. | Apoptosis inhibitor formulations for prevention of hearing loss |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4476116A (en) | 1982-12-10 | 1984-10-09 | Syntex (U.S.A.) Inc. | Polypeptides/chelating agent nasal compositions having enhanced peptide absorption |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4843155A (en) | 1987-11-19 | 1989-06-27 | Piotr Chomczynski | Product and process for isolating RNA |
| US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US6040138A (en) | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
| US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
| JP2001524926A (ja) | 1991-09-18 | 2001-12-04 | アフィマックス テクノロジーズ ナームロゼ フェンノートシャップ | オリゴマーの雑多ライブラリーの集合体を合成する方法 |
| ATE262374T1 (de) | 1991-11-22 | 2004-04-15 | Affymetrix Inc | Kombinatorische strategien für polymersynthese |
| US5384261A (en) | 1991-11-22 | 1995-01-24 | Affymax Technologies N.V. | Very large scale immobilized polymer synthesis using mechanically directed flow paths |
| US5556752A (en) | 1994-10-24 | 1996-09-17 | Affymetrix, Inc. | Surface-bound, unimolecular, double-stranded DNA |
| US5545531A (en) | 1995-06-07 | 1996-08-13 | Affymax Technologies N.V. | Methods for making a device for concurrently processing multiple biological chip assays |
| US5854033A (en) | 1995-11-21 | 1998-12-29 | Yale University | Rolling circle replication reporter systems |
| EP0880598A4 (en) | 1996-01-23 | 2005-02-23 | Affymetrix Inc | RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM |
| ZA976326B (en) | 1996-07-19 | 1998-02-03 | Amgen Inc | Analogs of cationic proteins. |
| US6391452B1 (en) | 1997-07-18 | 2002-05-21 | Bayer Corporation | Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations |
| ATE291097T1 (de) | 1997-10-31 | 2005-04-15 | Affymetrix Inc A Delaware Corp | Expressionsprofile in adulten und fötalen organen |
| US6020135A (en) | 1998-03-27 | 2000-02-01 | Affymetrix, Inc. | P53-regulated genes |
| US7060429B2 (en) * | 2001-02-22 | 2006-06-13 | University Of Maryland, Baltimore | Treatment of neurodegenerative diseases by altering levels of TrkB isoforms and/or TrkC isoforms |
| WO2003071872A1 (en) * | 2002-02-22 | 2003-09-04 | University Of Maryland, Baltimore | Novel treatment of neurodegenerative diseases by altering levels of trkb isoforms and/or trkc isoforms |
| US20060148749A1 (en) * | 2002-02-22 | 2006-07-06 | University Of Maryland | Novel treatment of neurodegenerative diseases by altering levels of TrkB isoforms and/or TrkC isoforms |
| US6846811B2 (en) * | 2002-04-22 | 2005-01-25 | Wisconsin Alumni Research Foundation | (20S) 1α-hydroxy-2α-methyl and 2β-methyl-19-nor-vitamin D3 and their uses |
| JP2007526022A (ja) * | 2003-10-24 | 2007-09-13 | メドトロニック・インコーポレーテッド | 炎症誘発性媒介物質の産生を減弱することによって神経性障害を処置する技法 |
| EP1752536A4 (en) * | 2004-05-11 | 2008-04-16 | Alphagen Co Ltd | POLYNUCLEOTIDE CAUSING RNA INTERFERENCE AND METHOD OF REGULATING GENE EXPRESSION WITH THE USE OF THE SAME |
| DE102005004343A1 (de) * | 2005-01-25 | 2006-08-10 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Behandlung von Phantomphänomenen |
| WO2006133353A2 (en) * | 2005-06-08 | 2006-12-14 | The University Of North Carolina At Chapel Hill | Methods of facilitating neural cell survival using non-peptide and peptide bdnf neurotrophin mimetics |
| CA2701189C (en) * | 2007-10-11 | 2017-05-16 | Biogen Idec Ma Inc. | Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell survival via administration of lingo-1 antagonists and trkb agonists |
| WO2011150347A2 (en) * | 2010-05-28 | 2011-12-01 | Pharmatrophix | Non-peptide bdnf neurotrophin mimetics |
| JP6054303B2 (ja) | 2010-12-30 | 2016-12-27 | ファウンデーション メディシン インコーポレイテッドＦｏｕｎｄａｔｉｏｎ Ｍｅｄｉｃｉｎｅ， Ｉｎｃ． | 腫瘍試料の多重遺伝子分析の最適化 |
| EP2630952A1 (en) * | 2012-02-23 | 2013-08-28 | Novagali Pharma S.A. | Self-preserved oil dispersions comprising boric acid |
| ES2479815B1 (es) * | 2012-12-24 | 2015-05-06 | Consejo Superior De Investigaciones Cientificas (Csic) | Peptido neuroprotector asi como su uso en el tratamiento de enfermedades cerebrovasculares y otras patologias del snc |
| WO2015066034A1 (en) * | 2013-10-28 | 2015-05-07 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for modulating neuronal excitability and motor behavior |
| US10066229B2 (en) | 2015-07-28 | 2018-09-04 | Otonomy, Inc. | Treatment using truncated Trk B and Trk C antagonists |
-
2016
- 2016-07-28 US US15/222,710 patent/US10066229B2/en active Active
- 2016-07-28 JP JP2018502404A patent/JP6923509B2/ja active Active
- 2016-07-28 EP EP16831375.7A patent/EP3328440A4/en not_active Ceased
- 2016-07-28 WO PCT/US2016/044570 patent/WO2017019905A1/en not_active Ceased
-
2018
- 2018-07-20 US US16/041,638 patent/US11034961B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018522013A5 (enExample) | ||
| CN107406852B (zh) | 用于莱伯氏先天性黑蒙的寡核苷酸疗法 | |
| JP2007527240A5 (enExample) | ||
| IL272761B1 (en) | Antisense oligomers for treatment of conditions and diseases | |
| CN103080314A (zh) | 显性突变基因表达抑制剂 | |
| US20060160759A1 (en) | Influenza therapeutic | |
| PE20220561A1 (es) | Metodos para el tratamiento de infeccion de hepatitis b | |
| JP2018512110A5 (enExample) | ||
| US20200399638A1 (en) | Oligonucleotides matching col7a1 exon 73 for epidermolysis bullosa therapy | |
| CN114514038A (zh) | 胶束纳米颗粒及其用途 | |
| JP2009535039A5 (enExample) | ||
| US20170233742A1 (en) | Compositions Comprising Small Interfering RNA Molecules for Prevention and Treatment of Ebola Virus Disease | |
| KR20180012255A (ko) | 이영양성 수포성 표피박리증 치료를 위한 안티센스 올리고뉴클레오타이드 | |
| TW201216988A (en) | Preventive or therapeutic agent for fibrosis | |
| WO2023023597A1 (en) | Virus-like particle | |
| CN106999573A (zh) | 佐剂组合物 | |
| US20210052630A1 (en) | Methods and Compositions for Preventing or Treating Heart Disease | |
| CN116157521A (zh) | 双链寡核苷酸和用于治疗covid-19的含有其的组合物 | |
| JP2023532536A (ja) | ｍｉＲＮＡ－４８５ハンチントン病の阻害剤 | |
| CN104245936B (zh) | 用于抑制TGF-β2表达的shRNA | |
| WO2020116537A1 (ja) | がん処置用ＲＮＡｉ分子 | |
| US10731161B2 (en) | Influenza-activated constructs and methods of use thereof | |
| JP2018513841A5 (enExample) | ||
| Zhou et al. | Mechanisms and barriers to RNAi delivery | |
| Seo et al. | Protection against lethal vaccinia virus infection in mice using an siRNA targeting the A5R gene |